This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Multiple sclerosis
  • /
  • Plasma levels of endothelial and B-cell-derived mi...

Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.

Read time: 1 mins
Published:25th Mar 2020
Author: Zinger A, Latham SL, Combes V, Byrne S, Barnett MH, Hawke S et al.
Ref.:Mult Scler. 2016 Mar 1. pii: 1352458516636959. [Epub ahead of print]

Background: No molecular marker can monitor disease progression and treatment efficacy in multiple sclerosis (MS). Circulating microparticles represent a potential snapshot of disease activity at the blood brain barrier.

Objectives and methods: To profile plasma microparticles by flow cytometry in MS and determine how fingolimod could impact endothelial microparticles production.

Results: In non-treated MS patients compared to healthy and fingolimod-treated patients, endothelial microparticles were higher, while B-cell-microparticle numbers were lower. Fingolimod dramatically reduced tumour necrosis factor (TNF)-induced endothelial microparticle release in vitro.

Conclusion: Fingolimod restored dysregulated endothelial and B-cell-microparticle numbers, which could serve as a biomarker in MS.


Read abstract on library site